Patents Examined by Sheela J. Huff
  • Patent number: 10172926
    Abstract: Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: January 8, 2019
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Ryuji Osawa
  • Patent number: 10174116
    Abstract: The present invention relates to HER2 (Human Epidermal Growth Factor Receptor 2) antibodies to prevent or treat cancers. The antibodies of the invention binds specifically to HER2 over-expressed in cancer cells (particularly, breast cancer and stomach cancer cells), specifically to an epitope on HER2 being different from epitope for trastuzumab. The CDR sequences of the present antibodies exhibit low similarity to CDR sequences of publicly known HER2 antibodies, addressing that the CDR sequences are unique. The antibodies of the present invention in combination with trastuzumab kill cancer cells with significantly enhanced cytotoxicity and therefore very effective in therapy of cancer (particularly, breast cancer and stomach cancer). Without wishing to be bound by theory, the enhanced efficacies of the combined therapy would address that the antibodies of the present invention bind to epitope on HER2 being different from epitope for trastuzumab, and inhibit HER2 in a cooperative manner with trastuzumab.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: January 8, 2019
    Assignee: ABCLON INC.
    Inventors: Jong-Seo Lee, Kyu-Tae Kim, Young-Ha Lee, Sook-Yeon Lee, In-Sik Hwang, Bong-Kook Ko
  • Patent number: 10166277
    Abstract: The invention relates to compositions of vault complexes for use as adjuvants for stimulating a cellular immune response to an antigen, for example a tumor antigen, and methods of using the vault complexes in the treatment of diseases, such as cancer.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: January 1, 2019
    Assignees: The Regents of the University of California, The United States of America represented by the Department of Veterans Affairs
    Inventors: Leonard H. Rome, Valerie A. Kickhoefer, Sherven Sharma, Steven M. Dubinett, Isaac Yang, Linda M. Liau, Kathleen A. Kelly, Jian Yang, Upendra K. Kar, Cheryl Champion, Janina Jiang
  • Patent number: 10167317
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: January 1, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Juliane Stickel, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
  • Patent number: 10155032
    Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: December 18, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
  • Patent number: 10144763
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Juliane Stickel, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
  • Patent number: 10143731
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: December 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10137202
    Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: November 27, 2018
    Assignee: Oncomatryx Biopharma, S.L.
    Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
  • Patent number: 10137185
    Abstract: The application provides a polypeptide comprising the sequence SLMTNLAAL (SEQ ID NO: 8), Ser 13 to Leu 21 of amino acid sequence shown in FIG. 1 or SEQ ID No 1, and having HLA-A2 haplotype binding activity, or a polynucleotide encoding said polypeptide. Vaccines containing the polypeptide or polynucleotides encoding the polypeptide are also provided.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: November 27, 2018
    Assignee: Nottingham Trent University
    Inventors: McArdle Stephanie, Rees Robert, A. Graham Pockley, Jaimy Saif
  • Patent number: 10123982
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: November 13, 2018
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10125196
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: November 13, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
    Inventors: Ugur Sahin, Michael Koslowski, Özlem Türeci
  • Patent number: 10117917
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: November 6, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10100121
    Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: October 16, 2018
    Assignee: AMGEN INC.
    Inventors: William Christian Fanslow, III, Carl Kozlosky, Jean Marie Gudas
  • Patent number: 10093715
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: October 9, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10081665
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: September 25, 2018
    Assignee: immatics biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10080777
    Abstract: The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit ?6?4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion, or inhibiting scarring and/or pathologic neovascularization.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: September 25, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Alan Rapraeger
  • Patent number: 10081664
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: September 25, 2018
    Assignee: immatics biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10064924
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: September 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Stickel, Daniel Kowalewski, Claudia Berlin
  • Patent number: 10058613
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: August 28, 2018
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Patent number: 10040865
    Abstract: The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: August 7, 2018
    Assignees: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.
    Inventors: David Scheinberg, Tao Dao, Cheng Liu, Su Yan